NEW YORK, Dec. 02, 2016 -- The Wall Street Journal’s Pulitzer Prize-winning senior editor Michael Siconolfi and Pulitzer Prize-winning investigative reporter John Carreyrou appeared on “Charlie Rose” on PBS this week for a wide-ranging discussion about their reporting on the health technology company, Theranos. The interview explores the full scope of the Journal’s year-long reporting on Theranos and its founder Elizabeth Holmes, including game-changing, behind the scenes moments from the investigation, as well as next steps.
|
|||||
The Wall Street Journal broke news about troubles at Theranos in a piece by John Carreyrou more than a year ago and has subsequently led on numerous stories about the tech startup.
The full interview can be watched at: https://charlierose.com/videos/29521
To subscribe to The Wall Street Journal, please visit: http://subscription.wsj.com
Steve Severinghaus Director, Communications [email protected]


Anta Sports Expands Global Footprint With Strategic Puma Stake
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Washington Post Publisher Will Lewis Steps Down After Layoffs
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 



